What is Carbon Biosciences?
Founded in 2021 and headquartered in Lexington, MA, Carbon Biosciences is dedicated to advancing gene therapy solutions. The company operates within the rapidly evolving biotherapeutics sector, aiming to address critical unmet needs through its proprietary technology platforms. Its focus on gene therapy positions it at the forefront of medical innovation, seeking to develop transformative treatments for a range of genetic disorders.
How much funding has Carbon Biosciences raised?
Carbon Biosciences has raised a total of $44M across 2 funding rounds:
Grant
$6M
Series A
$38M
Grant (2022): $6M with participation from Cystic Fibrosis Foundation
Series A (2022): $38M led by University of Tokyo Innovation Platform, Astellas Venture Management, Agent Capital, Longwood Fund, Camford Capital, and AJU IB INVESTMENT
Key Investors in Carbon Biosciences
Cystic Fibrosis Foundation
Headquartered Bethesda, Maryland, The Cystic Fibrosis Foundation is a 501 non-profit organization in the United States established to provide the means to cure cystic fibrosis and ensure that those living with CF live long and productive lives.
Astellas Venture Management
Founded in 2005 and headquartered in Brisbane, California, Astellas Venture Management is the corporate venture capital organization dedicated to reinforcing Astellas Pharma Inc.
Agent Capital
Agent Capital is a healthcare venture capital firm that invests in novel therapeutics and treatments aimed at addressing unmet patient needs. The firm collaborates with scientists, entrepreneurs, and investors to foster the development of innovative healthcare solutions across various stages of development. Their investment focus includes key areas such as rare diseases, oncology, neurology, and immunology. Agent Capital is dedicated to guiding biotech companies towards significant milestones and successful exits.
What's next for Carbon Biosciences?
With the recent infusion of capital, Carbon Biosciences is poised for a significant growth phase. The enterprise-level funding suggests a strategic move towards scaling operations, expanding research and development capabilities, and potentially advancing its lead candidates through clinical trials. The company's trajectory indicates a strong focus on achieving key developmental milestones and solidifying its market position in the biotherapeutics industry. Future developments will likely center on the successful translation of its gene therapy research into tangible patient benefits.
See full Carbon Biosciences company page
